Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/75791
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yan Lin | en_US |
dc.contributor.author | Fengkang Lin | en_US |
dc.contributor.author | Songyot Anuchapreeda | en_US |
dc.contributor.author | Rujirek Chaiwongsa | en_US |
dc.contributor.author | Suwit Duangmano | en_US |
dc.contributor.author | Bing Ran | en_US |
dc.contributor.author | Sakorn Pornprasert | en_US |
dc.date.accessioned | 2022-10-16T07:02:43Z | - |
dc.date.available | 2022-10-16T07:02:43Z | - |
dc.date.issued | 2021-01-01 | en_US |
dc.identifier.issn | 19438141 | en_US |
dc.identifier.other | 2-s2.0-85109067961 | en_US |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85109067961&origin=inward | en_US |
dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/75791 | - |
dc.description.abstract | Background: As a type of breast cancer that has relatively strong invasiveness, triple negative breast cancer (TNBC) seriously affects the survival of patients. microRNAs (miRNAs) have been shown to exert a prominent regulatory effect on the disease, among which miR-133b is reported to be involved in the pathological mechanism of breast cancer, but its role in TNBC remains unclear. Methods: In this study, real-time quantitative PCR (RT-qPCR) and Western blotting (WB) were performed for detecting the expressions of miR-133b, fibroblast growth factor receptor 1 (FGFR1), and Wingless/Integrated (Wnt)-β-catenin pathway markers (Wnt1, β-catenin, nuclear-β-catenin, p-GSK-3β, GSK-3β, cyclinD1, and FOXQ1). With TNBC cells and DDP-resistant TNBC cells (TNBC/DDP cells) used as research objects, their proliferation and apoptosis were measured by Cell Counting Kit-8 (CCK-8) assays and Flow cytometry, respectively. Then, the targeted relationship between miR-133b and FGFR1 was verified by Dual luciferase reporter gene assay (DLRGA). Results: In our study, miR-133b was down-regulated while FGFR1 up-regulated in TNBC. The ectopic expression of miR-133b remarkably inhibited the proliferation and colony formation but induced apoptosis of TNBC cells, and inactivated the Wnt-β-catenin pathway. The knockdown of FGFR1 had similar effects. Additionally, miR-133b targeted and negatively regulated FGFR1. Up-regulating miR-133b or down-regulating FGFR1 could enhance the proliferation and DDP sensitivity of TNBC cells or TNBC/DDP cells. Up-regulating FGFR1 could offset the anti-TNBC cell survival and DDP sensitization shown by ectopic expression of miR-133b. Conclusion: To sum up, miR-133b can inhibit the growth and DDP resistance of TNBC cells by targeting FGFR1 and inactivating the Wnt-β-catenin pathway. | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.title | Effect of miR-133b on progression and cisplatin resistance of triple-negative breast cancer through FGFR1-Wnt-β-catenin axis | en_US |
dc.type | Journal | en_US |
article.title.sourcetitle | American Journal of Translational Research | en_US |
article.volume | 13 | en_US |
article.stream.affiliations | Luzhou Medical College | en_US |
article.stream.affiliations | Chiang Mai University | en_US |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.